WeissLaw LLP: The Proposed Acquisition of Albany Molecular Research Inc. May Not Be In the Best Interest of AMRI Shareholders

NEW YORK, June 9, 2017

WeissLaw is investigating whether AMRI's Board acted to maximize shareholder value prior to entering into the agreement.  Notably, on May 9, 2017, AMRI reported it saw double-digit growth in first quarter of 2017.  It reported total revenue of $163.8 million, representing an increase of $58.2 million or 55% when compared to the $105.6 million reported in the same period of the previous year.  AMRI also reported an impressive 83% increase in EBITDA.  Additionally, the per-share offer price represents a meager 9% premium over the Company's June 5 closing price.  Finally, this deal will effectively privatize AMRI and exclude its shareholders from the Company's continued success and future growth prospects. 

Given these facts, WeissLaw is investigating whether AMRI's Board acted in the best interests of AMRI's public shareholders to maximize shareholder value prior to entering into the agreement.  If you own AMRI shares and would like more information about your rights or our investigation, or if you have information to share with us, please contact Joshua Rubin by telephone at (888) 593-4771 or by email at stockinfo@weisslawllp.com. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com or fill out the form on our website, http://www.weisslawllp.com/albany-molecular-research-inc/

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/weisslaw-llp-the-proposed-acquisition-of-albany-molecular-research-inc-may-not-be-in-the-best-interest-of-amri-shareholders-300471747.html

SOURCE WeissLaw LLP